Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -68.66% is 75% below its 5-year average of -39.25%, near the low end of its 5-year range (-68.66%–-25.85%).
50.77% below its 12-month average of -45.54%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.71%.
RETURN ON ASSETS (ROA)
-68.66%
RETURN ON ASSETS (ROA) AVG TTM
-45.54%
RETURN ON ASSETS (ROA) AVG 3Y
-39.28%
RETURN ON ASSETS (ROA) AVG 5Y
-39.25%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-50.77%
CURRENT VS 3Y AVG
-74.80%
CURRENT VS 5Y AVG
-74.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-112.80%
vs the sector median at left
TScan Therapeutics, Inc.
Market Cap
$16.82M
Return on Assets (ROA)
-68.66%
TTM Avg
-45.54%
3Y Avg
-39.28%
5Y Avg
-39.25%
Market Cap
$16.84M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$16.74M
Return on Assets (ROA)
-98.29%
TTM Avg
-314.03%
3Y Avg
-259.71%
5Y Avg
-198.18%
Market Cap
$16.64M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$17.07M
Return on Assets (ROA)
-30.06%
TTM Avg
65.41%
3Y Avg
-56.95%
5Y Avg
-76.50%
Market Cap
$16.52M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$17.31M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$17.39M
Return on Assets (ROA)
-39.68%
TTM Avg
-29.52%
3Y Avg
-26.86%
5Y Avg
-20.28%
Market Cap
$15.78M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| TScan Therapeutics, Inc. (TCRX) | $16.82M | -68.66% | -45.54% | -39.28% | -39.25% |
| Marker Therapeutics, Inc. (MRKR)vs › | $16.84M | -59.70% | -56.25% | -61.89% | -61.99% |
| Palatin Technologies, Inc. (PTN)vs › | $16.74M | -98.29% | -314.03% | -259.71% | -198.18% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.64M | -67.58% | -90.98% | -83.38% | -70.12% |
| PAVmed Inc. (PAVM)vs › | $17.07M | -30.06% | 65.41% | -56.95% | -76.50% |
| Dyadic International, Inc. (DYAI)vs › | $16.52M | -116.60% | -66.28% | -71.56% | -63.10% |
| Lipocine Inc. (LPCN)vs › | $17.31M | -49.72% | -28.29% | -39.08% | -40.04% |
| Cosmos Health Inc. (COSM)vs › | $17.39M | -39.68% | -29.52% | -26.86% | -20.28% |
| BioCardia, Inc. (BCDA)vs › | $15.78M | -154.34% | -227.23% | -240.86% | -184.63% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.68M | -38.41% | -84.87% | -95.12% | -75.66% |
ROA
-68.7%
ROE
-170.6%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -56.72% |
| 2024-12-31 | -34.36% |
| 2023-12-31 | -32.78% |
| 2022-12-31 | -33.26% |
| 2021-12-31 | -25.85% |
| 2020-12-31 | -52.53% |
| 2019-12-31 | -27.66% |
